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A longstanding unsettled question is whether
pancreatic b cells originate from exocrine duct cells.
We have now used genetic labeling to fate map
embryonic and adult pancreatic duct cells. We
show that Hnf1b+ cells of the trunk compartment of
the early branching pancreas are precursors of
acinar, duct, and endocrine lineages. Hnf1b+ cells
subsequent form the embryonic duct epithelium,
which gives rise to both ductal and endocrine line-
ages, but not to acinar cells. By the end of gestation,
the fate of Hnf1b+ duct cells is further restrained. We
provide compelling evidence that the ductal epithe-
lium does not make a significant contribution to
acinar or endocrine cells during neonatal growth,
during a 6 month observation period, or during
b cell growth triggered by ligation of the pancreatic
duct or by cell-specific ablation with alloxan followed
by EGF/gastrin treatment. Thus, once the ductal
epithelium differentiates it has a restricted plasticity,
even under regenerative settings.
INTRODUCTION
The pancreas is a mixed exocrine and endocrine gland. The
exocrine tissue consists of acinar cells that secrete digestive
enzymes into a branched ductal network that drains into the
gastrointestinal tract. The endocrine cells are grouped into islets
of Langerhans, which are embedded in the exocrine tissue,
and secrete insulin and other polypeptide hormones into the
bloodstream. Numerous studies have proposed that intercon-
versions among different pancreatic cell compartments are
possible, and in particular that epithelial cells of the adult
exocrine duct might represent a prevalent source of insulin
producing b cells (Laguesse, 1906; Bensley, 1911; Xu et al.,
2008; Inada et al., 2008; Suarez-Pinzon et al., 2005a; Gu and
Sarvetnick, 1993; Bonner-Weir et al., 1993; Rosenberg, 1995;DevelopmeRooman and Bouwens, 2004), although the data for this are con-
flicting (Teta et al., 2007; Nir et al., 2007; Dor et al., 2004).
All adult pancreatic epithelial cells are derived from an original
pool of pancreatic progenitors that evaginate from the foregut
endoderm after mouse embryonic age E8.5 (Herrera, 2000;
Kawaguchi et al., 2002; Gu et al., 2002). Such early multipotent
progenitors express lineage-selective transcription factors
such as Pdx1, Ptf1, Nkx6.1, Sox9, and Hnf1b (Lynn et al.,
2007; Jonsson et al., 1994; Hald et al., 2008; Haumaitre et al.,
2005). Between E11.5-E13.5, as the pancreas undergoes
branching morphogenesis, a subset of cells expressing Nkx6.1
gradually accumulate in more central trunk portions of the organ,
whereas Ptf1+ Cpa1+ cells form branching tips (Zhou et al., 2007;
Hald et al., 2008). How these morphogenetic changes relate to
the subsequent differentiation of pancreatic lineages is only
beginning to be defined. It is known that Cpa1+ cells from
E11.5–E13.5 can give rise to all pancreatic epithelial cell types
(Zhou et al., 2007), although the differentiation potential of trunk
cells has not been directly examined.
Definitive endocrine cells are largely formed from E13.5 to
E16.5, during the so called secondary transition (Pictet et al.,
1972). At this stage epithelial cells coexpressing Hnf1b and
Sox9 form duct structures. These embryonic duct cells have
been proposed to be direct precursors of the transient endo-
crine-committed Ngn3+ progenitor cells based on colocalization
studies of endogenous or transgenic marker proteins (Maestro
et al., 2003; Seymour et al., 2008; Lynn et al., 2007). On the other
hand, genetically labeled Pdx1+ cells from this stage give rise to
b cells but not to duct cells, thus raising the question as to
whether embryonic ductal structures containing putative precur-
sors of endocrine cells and adult exocrine ducts correspond to
the same lineages (Gu et al., 2002). A direct genetic labeling of
embryonic duct cells is therefore necessary to establish their
lineage relationship with other pancreatic cell types.
The b cell mass also undergoes major changes during the
neonatal period, and more gradually during subsequent post-
natal growth (Bonner-Weir, 2000; Wang et al., 1996; Dor et al.,
2004). The relative contribution of b cell replication or neogenesis
from non-b-cell sources during postnatal life is still under discus-
sion. Genetic or chemical labeling of b cells showed no evidencental Cell 17, 849–860, December 15, 2009 ª2009 Elsevier Inc. 849
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even after b cell ablation or pancreatectomy (Nir et al., 2007;
Dor et al., 2004; Teta et al., 2007). This contrasts with the
repeated finding that islet cells accumulate in the vicinity of ducts
during pancreatic regeneration (Gu and Sarvetnick, 1993; Wang
et al., 1996; Rooman and Bouwens, 2004; Rosenberg, 1995;
Xu et al., 2008). A recent study revealed facultative Ngn3+ Cyto-
keratin19+ progenitors in the vicinity of ducts during the robust
b cell expansion that follows pancreatic duct ligation (PDL),
raising the possibility that new b cells in this setting could be
formed from duct cells (Xu et al., 2008). On the other hand,
a genetic lineage tracing study used a human carbonic anhy-
drase II (CA2) promoter fragment to express Cre and CreER in
differentiated duct cells and concluded that ductal cells very
frequently dedifferentiate to give rise to new b cells formed in
neonates and after PDL (Inada et al., 2008). The prospect that
the pancreatic duct epithelium is a pool of facultative progenitor
cells has major implications for regenerative medicine, but the
discrepancies warrant an assessment with independent specific
tools to label pancreatic duct cells.
We have now engineered a hormone inducible Cre recombi-
nase in the Hnf1b locus to fate-map duct cells of the embryonic
and adult pancreas. We show that as the embryonic Hnf1b+
epithelium gradually acquires the anatomical configuration of
the pancreatic ductal network, it sequentially sets aside cells
for the acinar and endocrine lineages and finally takes on a differ-
entiated pancreatic duct phenotype. The results confirm earlier
suggestions that embryonic ducts give rise to both differentiated
endocrine and ductal cells but demonstrate that once the
pancreatic duct epithelium acquires a differentiated phenotype
it does not contribute significantly to new b cells that are formed
in diverse physiological or regenerative settings. These findings
establish fundamental lineage relationships of pancreatic epithe-
lial cells during embryonic and postnatal life.
RESULTS
Generation of Hnf1bCreER Mice
In the adult pancreas, Hnf1b is expressed in nearly all recogniz-
able nuclei of the epithelium that lines main, interlobular, intralob-
ular, and intercalated ducts, as well as in centroacinar cells
(Maestro et al., 2003; Nammo et al., 2008; Rukstalis and
Habener, 2007; see Figure S1 available online). In the embryonic
pancreas, it is also selectively expressed in the epithelium
lining duct structures that can be identified as early as E13.5
(Figure S2). To assess if pancreatic duct cells are precursors of
the different pancreatic lineages, we generated a BAC trans-
genic mouse strain in which tamoxifen-inducible Cre recombi-
nase (Cre-ERT2, hereafter referred to as CreER) was inserted in
exon 1 of Hnf1b (Hnf1bCreER) (Figure 1A). Immunofluorescence
analysis of CreER revealed that the transgene did not exhibit
significant mosaicism, and was expressed throughout the
pancreatic duct epithelium of Hnf1bCreER embryos and adult
mice, but not in non transgenic littermates (Figures 1B–1F).
To validate the model for lineage tracing experiments, we
crossed Hnf1bCreER with the R26R reporter line (Figure 1G).
In double-transgenic mice, tamoxifen (TM) or 4-hydroxytamoxi-
fen (4-OHT) treatment results in nuclear translocation of CreER
(Figures 1C and 1D), which is expected to lead to the recombina-850 Developmental Cell 17, 849–860, December 15, 2009 ª2009 Elstion of the silenced Lacz reporter in theR26R locus within 6–36 hr
(Hayashi and McMahon, 2002; Zhou et al., 2007). TM treatment
of adult Hnf1bCreER/R26R mice thus resulted in b-galactosi-
dase (b-gal) detection by immunofluorescence or X-gal histo-
chemistry in up to 65% of Hnf1b+ duct cells (Figures 1H, S3A,
and S3C). b-gal was detected in large and small ducts, as well
as in centroacinar cells, previously proposed to be acinar and
endocrine progenitors (Nagasao et al., 2003; Figure S3A).
Hnf1b+ duct cells that were b-gal+ and b-gal were indistinguish-
able with respect to epithelial morphology, expression of CreER,
Ki67, or ductal markers Hnf1b, Sox9, Muc1, and CK19 (Fig-
ure S4). Hnf1bCreER/R26R embryos or postnatal mice that did
not receive TM or 4-OHT did not express b-gal (Figures 1I,
S3B, and S3C). Thus, TM treatment of Hnf1bCreER/R26R mice
specifically labels the Hnf1b + pancreatic duct epithelium.
Hnf1b+ Cells from E11.5–13.5 Give Rise to Duct, Acinar,
and Endocrine Cells
To test the fate of Hnf1b+ cells of the early branching epithelium,
we first defined the cellular domain expressing endogenous
Hnf1b at E11.5–E13.5. We also examined CreER expression to
assess if the transgenic model faithfully labels Hnf1b+ cells. At
E11.5 Hnf1b and CreER are expressed in most epithelial cells,
often in cells that also express Cpa1 (Figures 2A and S2A).
Subsequently, both Hnf1b and CreER localize to central trunk
cells, rather than to Cpa1+ branching tip cells (Figures 2B–2D,
S2B, and S2C). We nevertheless noticed that Cpa1 is expressed
in a progressively diminishing number of non-tip Hnf1b+ and
CreER+ cells, even as late as E13.5 (Figures 2D and S2B). By
E13.5 Hnf1b+ and CreER+ cells form primitive duct-like struc-
tures, some of which already accumulate acinar secreted prod-
ucts in the lumen (Figure S2B).
We next treated pregnant mice with 4-OHT at either E11.5
(n = 4) or E12.5 (n = 4), and then analyzed b-gal in offspring at
the end of gestation (not shown) and in early adulthood
(Figure 2E). We used 1.5 mg 4-OHT i.p., because higher doses
caused embryonic lethality. At both injection times b-gal was
observed in a comparable fraction of differentiated ductal,
acinar, and endocrine cells (Figures 2F–2J), although the labeling
frequency in acinar cells was somewhat lower when 4-OHT was
injected at E12.5. These results indicate that all three major
pancreatic lineages are derived from Hnf1b+ trunk cells of the
early branching epithelium (Figure 2K).
Duct Cells of the Second Transition Give Rise
to Differentiated Duct and Endocrine Cells
Definitive pancreatic endocrine cells are largely formed during
the secondary transition, spanning from E13.5 to E16.5 (Pictet
et al., 1972). At this stage, the Hnf1b+ epithelium has already
acquired a characteristic pancreatic exocrine duct network
structure (Maestro et al., 2003; Nammo et al., 2008; Rukstalis
and Habener, 2007; Figure S2B). To assess if CreER recapitu-
lates Hnf1b expression at this stage, we treated Hnf1bCreER/
R26R pregnant mice with 4-OHT at E13.5, and 1 day later
detected nuclear CreER expression in 98% of Hnf1b+ duct cells
(Figures 3A and 3E). Non-duct cells rarely expressed CreER,
although it was detected in 9% of Ngn3+ cells, consistent with
the reported low-level expression of Hnf1b in a subset of
Ngn3+ cells (Maestro et al., 2003; Figures 3B–3E).evier Inc.
Figure 1. Generation of the Hnf1bCreER Mouse
(A) Summary of the recombineering cloning strategy and schematic map of the Hnf1bCreER BAC transgene. Note that the transgenic construct contains EGFP
but it was not detected by endogenous fluorescence or immunofluorescence.
(B) CreER was not detected in wild-type cells.
(C and D) CreER was expressed in the ductal epithelium of Hnf1bCreER E14.5 embryos and translocates to the nucleus after 4-OHT treatment.
(E and F) CreER was expressed broadly throughout the epithelium of adult pancreatic ducts only in transgenics.
(G) Schematic of the genetic strategy to irreversibly label Hnf1b+ duct cells and their progeny by transient TM treatment of Hnf1bCreER/R26R mice.
(H and I) b-gal was expressed in a major fraction of Hnf1b+ duct cells from TM-treated, but not in nontreated adult Hnf1bCreER/R26R mice. Scale bar 50 mm.
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from this stage, we injected 4-OHT at E13.5 and studied b-gal
expression after a short chase period (Figure 3F). Six hours post-
injection b-gal was exclusively detected in a small number of
ductal Hnf1b+ cells (not shown). Twenty hours after 4-OHT injec-
tion, b-gal was observed in a larger number of cells, 94.1% of
which coexpressed Hnf1b (Figure 3O). Among non-Hnf1b-Developmeexpressing cells, b-gal+ cells were thus more frequent than
CreER+ cells, as expected if there are transitions of Hnf1b+ cells
to Hnf1b cells during the 20 hr period. For example, the frac-
tion of Ngn3+ and endocrine cells expressing b-gal at E14.5
was >4-fold higher than expected from their CreER labeling
rates, as anticipated if endocrine progenitors arising during
this time frame are derived from Hnf1b+ duct cells (not shown).ntal Cell 17, 849–860, December 15, 2009 ª2009 Elsevier Inc. 851
Figure 2. Hnf1b+ Cells from E11.5–E13.5
Give Rise to Acinar, Ductal, and Endocrine
Cells
(A and B) At E11.5 CreER and Cpa1+ domains are
largely coincident. In E12.5 pancreas, Cpa1 was
primarily expressed in tips (arrows), although non
tip double-positive cells were also observed
(arrowheads).
(C and D) In E12.5–E13.5 CreER was in centrally
located trunk cells but very rarely in branching tip
cells. The image in d was taken 24 hr after treat-
ment with 4-OHT.
(E) Schematic of the lineage tracing experiment.
(F–I) Adult mice injected with 4-OHT at E12.5
showed b-gal expression in Hnf1b+ duct cells,
amylase+ acinar cells, and insulin+ and glucagon+
endocrine cells (arrowheads).
(J) Percent of each pancreatic cell type expressing
b-gal in adult mice treated with 4-OHT at E11.5
(n = 4) or E12.5 (n = 4). Ins, Glu, and Acin are b cells,
a cells, and acinar cells, respectively. Similar
findings were encountered when the chase was
completed at E18.5. Cell counts are provided in
the Table S1.
(K) Summary of lineage tracing results. Scale bar
50 mm.
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reinforced the CreER immunolocalization results showing that
the majority of recombination events occurred in Hnf1b+ ductal
cells.
To determine the fate of Hnf1b+ duct cells during the
secondary transition, we studied b-gal expression at the end of
embryogenesis after 4-OHT treatment at E13.5 (Figure 3F).
Whereas at E14.5 the vast majority of b-gal+ cells were Hnf1b+
cells, by E18.5 nearly 50% were Hnf1b (Figures 3G–3O). This852 Developmental Cell 17, 849–860, December 15, 2009 ª2009 Elsevier Inc.indicated that during the secondary tran-
sition of pancreas development a sizeable
fraction of ductal cells had transitioned to
other pancreatic lineages.
We next determined which pancreatic
cell types originate from E14 embryonic
duct cells. The proportion of Hnf1b+
ductal cells expressing b-gal at E14.5
was maintained at E18.5 (1.93% ±
0.55%, n = 8, versus 2.07% ± 0.63%,
n = 5, respectively; p = N.S.), consistent
with E18.5 duct cells being derived from
earlier duct cells. The b-gal labeling rate
of acinar cells was very low and did not
increase between E14.5 and E18.5, thus
showing that duct cells do not make
a significant contribution to the major
expansion of acinar cells that takes
place during this window of development
(Figure 3P). In sharp contrast, the b-gal
labeling rates of insulin+ or glucagon+
cells increased > 10-fold between E14.5
and E18.5, reaching a similar b-gal
labeling rate as that of duct cells (b-gallabeling rate in insulin+ cells at E14.5 versus E18.5: 0.14 ± 0.24
versus 2.22 ± 0.8, p < 0.005; glucagon+ cells: 0.21 ± 0.18 versus
2.44 ± 0.64, p < 0.005; Figures 3K–3N and 3P). Similar results
were observed for E13.5-treated embryos chased at 4 weeks
of age (not shown). These findings indicate that pancreatic
duct cells of the secondary transition are the precursors of differ-
entiated duct and endocrine cells, yet unlike earlier Hnf1b+
pancreatic progenitors they do not give rise to acinar cells
(Figure 3Q).
Figure 3. The Ductal Epithelium of the
Secondary Transition Gives Rise to Duct
and Endocrine but Not Acinar Lineages
(A–D) In E14.5 pancreas CreER was expressed
throughout the Hnf1b+ epithelium, but only rarely
in cells expressing insulin (Ins), glucagon (Glu),
Ngn3, or Cpa1. The mouse anti-Hnf1b antibody
used in the dual immunolocalization experiment
shown in (A) produces extracellular unspecific
staining that is not seen with other Hnf1b sera.
Arrows in (C) illustrate b-gal+ Ngn3+ cells, although
most Ngn3+ cells were b-gal.
(E) Percent of CreER expressing cells for each
pancreatic cell type one day after the 4-OHT pulse
(n = 4).
(F) Schematic of the lineage tracing experiment.
(G–N) When embryos were pulsed at E13.5 and
analyzed at E14.5, b-gal was mostly detected in
Hnf1b+ duct cells. Arrows in (G) show such
double-labeled duct cells. When chased at E18.5,
b-gal was detected in Hnf1b+ duct cells and
endocrine cells, but rarely in Cpa1+ acinar cells.
Arrowheads in (K) show b-gal+ cells that are not
in ducts; arrows in (L) and (M) show b-gal+ cells
expressing endocrine markers.
(O) In embryos pulsed at E13.5, the percent of
b-gal+ cells that do not coexpress the ductal
marker Hnf1b increased by nearly 10-fold between
E14.5 and E18.5.
(P) Quantification of b-gal-expressing cells for
each pancreatic cell type at E14.5 (n = 8) (dark
blue) and E18.5 (n = 5) (gray). Ins, Glu, and Acin
are b cells, a cells, and acinar cells, respectively.
Cell counts are provided in Table S1. *p < 0.005;
NS: nonsignificant; ND: not determined. Similar
findings were observed in animals chased at
4 weeks of age.
(Q) Summary of lineage tracing results. Scale bar
30 mm.
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During the first few days after birth b cells undergo a major
increase in mass (Scaglia et al., 1997; Wang et al., 1996). To
determine if new b cells originate from duct cells during this
stage, we treated pregnant females shortly before delivery (at
E18.5) and analyzed Hnf1bCreER/R26R offspring at postnatal
day 14 (P14). CreER during the pulse period (n = 3) and b-gal
at the P14 chase time point (n = 3) were almost exclusively
expressed in the pancreatic duct epithelium (Figures 4A–4J).
This showed that neonatal b cell or acinar cell growth does not
result from the differentiation of pancreatic duct cells (Figure 4K).
Throughout subsequent postnatal life the b cell mass shows
a progressive augmentation that parallels the increase in body
mass (Montanya et al., 2000; Dor et al., 2004; Wang et al.,Developmental Cell 17, 849–860, D1996). To assess if newly formed b cells
originate from the ductal epithelium, we
treated young adult Hnf1bCreER/R26R
mice by oral gavage with three doses of
TM over 5 days. Shortly after completion
of the TM treatment, nuclear CreER and
b-gal were detected selectively in the
epithelium of common, interlobular, andintralobular ducts, as well as in centroacinar cells, in keeping
with the expression pattern of Hnf1b (n = 6; Figures S1, S4,
and 4L–4P and not shown). Average b-gal labeling efficiencies
with this labeling protocol were 41%. Six months after TM
treatment, the proportion of endocrine or acinar cells that were
labeled with b-gal did not change (n = 4; Figures 4Q–4V). Thus,
during the physiological postnatal growth of the pancreas, pre-
existing duct cells give rise to duct cells, but not to endocrine
or acinar cells (Figure 4W).
Duct Cells Do Not Contribute to b Cell Growth after
Pancreatic Duct Ligation
Many studies have proposed that the robust increase of b cell
mass that follows pancreatic duct ligation (PDL) is derivedecember 15, 2009 ª2009 Elsevier Inc. 853
Figure 4. Duct Cells Do Not Contribute
Significantly to Growth of Endocrine or
Acinar Cells in Neonatal or Long-Term Post-
natal Growth
(A–D) At P0, CreER was expressed in all CK19-
expressing duct cells, but not in endocrine or
acinar cells.
(E) Quantification of the percent of CreER+ cells for
each pancreatic cell type one day after the 4-OHT
pulse (n = 3).
(F) Schematic of the lineage tracing experiment.
(G–I) Embryos pulsed at E18.5 and analyzed two
weeks after birth showed b-gal almost exclusively
in duct cells. Hollow arrowheads in (I) point to
amylase in lumen of ducts.
(J) Quantification of b-gal+ cells for each pancre-
atic cell type at P14 (n = 3). Ins, Glu, and Acin are
b cells, a cells, and acinar cells, respectively. Cell
counts are provided in Table S1.
(K) Summary of lineage tracing results.
(L–O) In young adult mice, CreER was expressed
in all CK19-expressing duct cells, but not in endo-
crine or acinar cells after the TM pulse.
(P) Quantification of the percent of CreER+ cells for
each pancreatic cell type one week after the TM
pulse in young adults (n = 4).
(Q) Schematic of the lineage tracing experiment.
(R–U) In mice pulsed at 8 weeks and analyzed
6 months later b-gal was almost exclusively
located in duct cells.
(V) Quantification of b-gal+ cells for each pancre-
atic cell type 1 week (n = 6) and 6 months (n = 4)
after TM treatment (blue and gray bars, respec-
tively). Ins, Glu, and Acin are b cells, a cells, and
acinar cells, respectively. NS: nonsignificant. Cell
counts are provided in Table S1.
(W) Summary of lineage tracing results. Scale bar
50 mm.
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Plasticity of Pancreatic Duct Cellsfrom differentiated adult duct cells (Xu et al., 2008; Inada et al.,
2008; Wang et al., 1995). To test this hypothesis, we treated adult
Hnf1bCreER/R26R mice with TM using a 2 week i.p. protocol,
which resulted in an average labeling efficiency of 40% of
duct cells. Three weeks later, we performed PDL exactly as
described in (Xu et al., 2008; Figure 5A). We verified that PDL
led to the expected increase in b cell mass and Ngn3 expression
in the ligated portion of the pancreas, but not in the nonligated
tail portion or sham treated mice (Figures 5B, 5C, and 5D).
One week after the PDL procedure, when the peakofbcell mass
increase occurs, we independently examined both X-gal (n = 6)
and b-gal (n = 3) staining in the non-ligated (control) and ligated854 Developmental Cell 17, 849–860, December 15, 2009 ª2009 Elsevier Inc.portions of the pancreas. The nonligated
portion showed X-gal and b-gal labeling
in the ducts (Figures 5E, 5H, and 5I). In
the ligated portion, a profuse X-gal and
b-gal labeling was observed in cells form-
ing the tubular complexes that are charac-
teristically formed after PDL (Figures 5F,
5J, and 5K). However, no increase in
X-gal or b-gal labeling was observed in
endocrine cells (Figures 5G and 5L). Thus,
preexisting duct cells contribute to newduct cells and tubular complexes formed after PDL, in contrast
to earlier suggestions that tubular complexes result from the invo-
lution of acinar cells (Wang et al., 1995) yet do not make a signifi-
cant contribution to newly formed endocrine cells (Figure 5M).
Duct Cells Do Not Contribute to b Cell Regeneration
in a Cell Ablation Model
Duct cells are also thought to be the origin of b cell regeneration
in mice that undergo ablation of b cells and are then treated with
EGF and gastrin (Rooman and Bouwens, 2004). We treated mice
with three doses of TM over 5 days by oral gavage. Two weeks
later, b cells were ablated by alloxan treatment, followed by
Figure 5. Duct Cells Only Contribute to Duct
Cell Growth after PDL
(A) Schematic of the lineage tracing experiment.
(B–D) PDL led to the expected increase in b cell
mass and Ngn3 mRNA expression in the ligated
portion of the pancreas (n = 7). Ngn3 mRNA is
expressed as a percentage of Ngn3 mRNA in
duodenum. No Ngn3 mRNA was detected after
40 cycles in unligated pancreas. T: pancreatic
tail; H: pancreatic head. *p < 0.005.
(E and F): After PDL X-gal stained the ductal
epithelium, including centroacinar (ca), interca-
lated (ic), and interlobular (il) ducts in the nonli-
gated portion of the pancreas. In the ligated
portion of the pancreas X-gal was observed in
ducts and tubular complexes.
(G) No increase in X-gal+/insulin+ cells was
observed in ligated versus nonligated portions of
the pancreas after PDL (n = 6).
(H–K) After PDL b-gal was detected by immuno-
fluorescence in duct cells of the ligated and
nonligated portions of the pancreas, but not in
endocrine cells.
(L) Percentage of b-gal+ cells for each pancreatic
cell type after PDL (n = 3). Ins, Glu, and Acin are
b cells, a cells, and acinar cells, respectively.
Note that very few acinar cells remain after PDL,
all of which were b-gal. Cell counts are provided
in Table S1.
(M) Summary of lineage tracing results. NS:
nonsignificant. Scale bar 50 mm.
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Plasticity of Pancreatic Duct Cellsgastrin plus EGF treatment with miniosmotic pumps during
1 week to induce b cell regeneration (Rooman and Bouwens,
2004; Figure 6A). As expected, alloxan-EGF/gastrin-treated
mice, but not alloxan-only controls, showed a normalization of
blood glucose (Figure 6B), and a 9-fold increase in the fraction
of pancreatic area covered by insulin-producing cells, consistent
with the expected regeneration of pancreatic b cells (Figure 6C).
Despite the increase in b cell mass in alloxan/EGF-gastrin
treated mice, b-gal remained restricted to ducts, indicating
that these do not make a significant contribution to newly formed
b cells in this model (Figures 6D–6F).
DISCUSSION
A pancreatic ductal origin of islet cells was suggested as early
as 1906 (Laguesse, 1906; Bensley, 1911). Since then, a vastDevelopmental Cell 17, 849–860, Dliterature has advocated this notion
(Xu et al., 2008; Rooman and Bouwens,
2004; Inada et al., 2008; Bonner-Weir
et al., 1993; Gu and Sarvetnick, 1993;
Rosenberg, 1995; Suarez-Pinzon et al.,
2005a). We have now exploited the selec-
tive expression of Hnf1b in the epithelium
that first forms the trunk compartment
of the branching pancreas, later the
embryonic ducts, and finally differenti-
ated pancreatic ducts. We genetically
labeled pancreatic Hnf1b+ epithelial cells
at different time points and observedsequential changes in their differentiation potency (Figure 7).
We thus show that before E13.5 Hnf1b+ epithelial cells are
progenitors of all major pancreatic cell types. Shortly afterwards,
the Hnf1b+ duct epithelium gives rise to adult duct and endocrine
cells but no longer contributes to the acinar lineage. By the end of
gestation, the fate of differentiated duct cells is restricted, even
during regenerative settings (Figure 7).
Early Hnf1b+ Trunk Cells Give Rise to All Major
Pancreatic Epithelial Cells
Hnf1b is expressed in the multipotent cells of the nascent
pancreatic endoderm (Haumaitre et al., 2005). However, the
cellular competence of Hnf1b+ cells during subsequent stages
is unclear. The current study showed that during E11.5 to
E13.5 Hnf1b+ cells accumulate in the trunk compartment and
give rise to adult differentiated endocrine, exocrine, and ductalecember 15, 2009 ª2009 Elsevier Inc. 855
Figure 6. Ductal Cells Are Not a Major Source of b Cells after Alloxan Ablation and EGF/Gastrin Treatment
(A) Schematic of the lineage tracing experiment.
(B) Treatment with EGF/Gastrin at day 0 (D0) after alloxan ablation of b cells at day 1 (D1) significantly lowered glycemia compared to control mice that only
received alloxan. The results show nonfasting glycemias (mg/dl) of mice treated with alloxan (n = 6) (blue) and mice treated with alloxan + EGF/Gastrin (n = 5)
(red). *p < 0.01.
(C) Treatment with EGF/Gastrin significantly increased the percentage of the total pancreatic area that was immunoreactive for insulin, as compared to controls.
*p < 0.0001.
(D) After EGF/Gastrin-induced regeneration, X-gal staining remained restricted to ducts and was absent from islets.
(E) Despite the regeneration observed in EGF/Gastrin-treated mice (n = 5), duct and b cell X-gal labeling rates are not different than in control transgenic mice that
only received alloxan (n = 3) (p = NS).
(F) Summary of lineage tracing results. Scale bar = 100 mm.
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ing tip cells from this same stage also generate all major pancre-
atic cell types. The similar outcome of labeling cells during
E11.5–E13.5 in Hnf1bCreER and Cpa1CreER mice may be due
to the existence of a subset of precursors that express both
Hnf1b and Cpa1 during this stage, or because multipotent
progenitors at this stage can be either Hnf1b+ Cpa1 or Hnf1b
Cpa1+ (Figure 7). The important conclusion is that even as late as
E13, the Hnf1b+ cellular domain retains the ability to give rise to
all three major pancreatic lineages.
DuctCells of theSecondary TransitionGiveRise toAdult
Endocrine and Duct Cells, but Not to Acinar Cells
At E13.5–E16.5 the ductal epithelium is composed of cells that
coexpress Hnf1b, Sox9, Hnf6, and mucin, and already adopts
a characteristic pancreatic exocrine duct network structure
(Maestro et al., 2003; Lynn et al., 2007; Pierreux et al., 2006;
Figures S2B–S2D). We examined whether this epithelium gives
rise to transient Ngn3+ endocrine progenitors. Previous work856 Developmental Cell 17, 849–860, December 15, 2009 ª2009 Elsrevealed Ngn3+ cells intercalated in the Hnf1b+ epithelium of
ducts and that a subset of Ngn3+ cells coexpress Hnf1b,
suggesting a direct transition between ductal Hnf1b+ and Ngn3+
cells (Maestro et al., 2003). Analogous observations were later
made with immunolocalization studies of Sox9 and Ngn3 in
wild-type mice, or with a Sox9-GFP transgenic line (Lynn
et al., 2007; Seymour et al., 2008). The latter showed GFP
expression in endocrine cells, which can be interpreted as an
indication that duct cells give rise to endocrine cells because
of the long half life of GFP but can also result from inappro-
priate transgenic expression of GFP (Seymour et al., 2008). A
further difficulty to interpret Sox9 GFP studies is that endoge-
nous Sox9 is normally expressed in most Ngn3 cells (Seymour
et al., 2008). Conclusive lineage tracing requires that one can
document the nature of labeled and chased cells, and this
cannot be achieved through colocalization studies. The current
study thus provides direct genetic labeling evidence that
Hnf1b+ duct cells of the secondary transition are precursors
of Ngn3+ endocrine progenitors. It also demonstrated that theevier Inc.
Figure 7. Summary of Lineage Relation-
ships between Hnf1b+ Cells and Other
Pancreatic Cell Types
A more detailed explanation is provided in the
Discussion.
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Plasticity of Pancreatic Duct CellsHnf1b+ embryonic duct domain gives rise to differentiated duct
cells.
The secondary transition is also the stage when amylase
begins to be detected as a differentiation marker of acinar cells,
coinciding with the formation of insulin-expressing cells (Pictet
et al., 1972). Our findings, however, indicate that progenitor cells
from the Hnf1b+ epithelium are allocated to an acinar fate before
the secondary transition. This suggests that the expansion of the
acinar cell compartment during embryogenesis is dependent on
their proliferation, but not on a continuous influx of progenitors
from duct cells. The acinar lineage in turn does not contribute
to other lineages during the secondary transition (Zhou et al.,
2007). Current findings thus define separable time points at
which acinar and endocrine lineages are set aside from the
Hnf1b+ pancreatic epithelium (Figure 7).
Lack of Plasticity of Postnatal Duct Cells In Vivo
Postnatally, the cells that form the differentiated epithelium of
large and small ducts coexpress several markers in common
with embryonic duct progenitors, including Hnf1b, Sox9, and
Muc1. The current data, however, show that the differentiated
epithelium lacks the plasticity of embryonic duct cells. We tested
this in the PDL pancreatic injury model, which was recently
shown to induce formation of new b cells from Ngn3+ progenitor
cells, frequently located near ducts (Xu et al., 2008). Although
this process is highly suggestive of a recapitulation of embryonic
development, the present study provides genetic lineage tracing
evidence that the pancreatic duct epithelium does not contribute
a significant source of progenitors in the b cell growth response
to PDL. Furthermore, despite previous suggestions that treat-
ment with EGF and gastrin afterbcell ablation causes neogenesis
from ducts (Rooman and Bouwens, 2004; Suarez-Pinzon et al.,
2005b), our analysis again failed to support this cellular origin.
The Hnf1bCreER model labels the differentiated duct epithe-
lium of the adult pancreas with up to 65% efficiency. In each
experiment, many duct cells remain unlabeled, consistent with
the notion that in CreER models ligand treatment typically
causes recombination only in a random subset of the cells that
express the recombinase. However, since we did not detect aDevelopmental Cell 17, 849–860, Dductal origin of b cells, we considered an
alternate hypothetical scenario, namely
that there is heterogeneity within the adult
Hnf1b+ ductal epithelium and putative
Hnf1b+ stem cells are consistently spared
from labeling. Several lines of evidence
indicate that this does not occur. First,
we show that the Hnf1bCreER model
does label ductal Hnf1b+ progenitors in
the embryo, using far lower doses of
ligand. Second, if there is an Hnf1b+
ductal stem cell subpopulation that issystematically spared from recombination, it should either not
express the recombinase, or express distinctly lower levels;
however, we show that CreER is expressed in virtually all cells
expressing Hnf1b, CK19, mucin, or Sox9, including main, inter-
lobular, intralobular, and centroacinar duct cells. Furthermore,
there was no visible heterogeneity in CreER levels throughout
the Hnf1b+ duct epithelium. Third, Hnf1b+ duct cells that did
and did not undergo Cre recombination after a short term pulse
where indistinguishable with respect to the above mentioned
duct markers, epithelial morphology, or CreER expression
(Figure S4). Importantly, they did not differ in proliferation indexes
or in cell growth, since ductal b-gal labeling indexes remained
stable even after the robust duct cell proliferation that occurs in
PDL (Walker et al., 1992; Figures 5G and 5L). Collectively, these
results indicate that the Hnf1bCreER model broadly labels cells
that represent the differentiated pancreatic duct epithelium.
Consequently, it shows that this epithelium is not a prevalent
source of acinar and endocrine cells under the examined condi-
tions, without addressing whether putative stem cells that do not
express Hnf1b are located in the vicinity of ducts.
These results contrast with those obtained with transgenic
mice expressing Cre and CreER driven by the human carbonic
anhydrase II (CA2) promoter (Inada et al., 2008). That study led
to the conclusion that during neonatal and postnatal physiolog-
ical growth or after PDL a major fraction of endocrine and acinar
cells originate from differentiated duct cells (Inada et al., 2008).
The discrepancy with our model is plausibly due to differences
in the cell types that were labeled. This cannot be clarified by
comparing the expression of endogenous carbonic anhydrase
II with CreER in Hnf1bCreER mice, because carbonic anhydrase
II expression in mice is not restricted to pancreatic ducts, which
is why a human CA2 promoter fragment was employed in the
transgenics (Inada et al., 2008). Because a quantitative analysis
of CreER and b-gal cell-specific expression patterns at the
outset of the lineage tracing studies has not been described in
CA2CreER mice, and significant b-gal expression was reported
in untreated control mice (Inada et al., 2008), more studies are
needed to interpret the different outcome of the two genetic
lineage tracing models.ecember 15, 2009 ª2009 Elsevier Inc. 857
Developmental Cell
Plasticity of Pancreatic Duct CellsMore generally, our findings are at odds with countless studies
that claimed or assumed that b cells are derived from ducts
based on their proximity during normal growth or regeneration
(Xu et al., 2008; Gu and Sarvetnick, 1993; Rosenberg, 1995;
Rooman and Bouwens, 2004; Bonner-Weir et al., 1993; Phillips
et al., 2007). Several factors can reconcile such observations
with ours. First, it is likely that pancreatic ducts provide or share
a tissue milieu that favors the formation of new endocrine cells.
On the other hand, endocrine cells that normally reside in the
duct epithelium could expand under certain circumstances and
give rise to visible endocrine cell clusters. Finally, our results
do not exclude rare instances of metaplasia, whereby a pancre-
atic duct cell gives rise to an endocrine cell. We simply show that
this mechanism does not represent a quantitatively significant
contribution to b cell growth.
Implications for Human Disease
HomozygousHnf1bmutations in mice and heterozygousHNF1B
mutations in humans cause pancreas disgenesis, although the
exact role of Hnf1b in pancreas organogenesis is only beginning
to be defined (Haumaitre et al., 2005, 2006). The current study
sheds light on the differentiation potential of Hnf1b-expressing
cells at different developmental stages, and thus provides key
information to interpret future studies using stage-specific
Hnf1b mutations in mice, or pancreatic samples from HNF1B-
deficient human individuals.
Our results also have implications for regenerative strategies
to treat common forms of diabetes. The current study together
with recent lineage tracing studies of acinar and b cells (Desai
et al., 2007; Nir et al., 2007; Teta et al., 2007; Dor et al., 2004;
Strobel et al., 2007) argue against the existence of major inter-
conversions between the major differentiated cellular lineages
of the late embryo and postnatal pancreas. Such studies, how-
ever, should not be taken as evidence that pancreatic cell fates
cannot be modified. Recent observations, for example, indicate
that acinar cells can be reprogrammed to b cells, both in vitro
and in vivo (Baeyens et al., 2009; Zhou et al., 2008; Minami
et al., 2005). The finding that adult duct and endocrine cells are
derived from a common progenitor pool at a relatively late stage
of embryogenesis raises the intriguing possibility that differenti-
ated duct cells may be an epigenetically privileged cell target for
reprogramming b cells by artificial in vitro or in vivo strategies.
EXPERIMENTAL PROCEDURES
Generation of Hnf1bCreER Transgenic Mice
All animal experiments were conducted as approved by the Ethical Committee
of Animal Experimentation of our institutions and in accordance with national
regulations.
To generate Hnf1bCreER transgenic mice, we modified a BAC clone
containing the Hnf1b locus (RP23-304H7) as described in Liu et al. (2003).
We replaced exon 1 of Hnf1b with a targeting vector containing an Hnf1b
promoter fragment, Cre-ERT2, IRES, d2EGFP (a destabilized variant of EGFP),
the b-globin polyadenylation site, a FRT/Neomycin resistance/FRT cassette,
and an intron 1 fragment that flanks exon 1 of Hnf1b (Figure 1A).
We first generated a targeting vector that was electroporated in EL250 cells
containing BAC RP23-304H7, and induced homologous recombination by
a 42C heat shock as described (Liu et al., 2003). Dual chloramphenicol/
kanamycin resistant clones carrying the predicted BAC insert were treated
with arabinose to activate inducible Flp recombinase, thereby removing the
FRT-Neo-FRT cassette. The recombined BAC was digested with NotI to sepa-858 Developmental Cell 17, 849–860, December 15, 2009 ª2009 Elsrate pBACe3.6 backbone from the insert, which was purified by Sepharose
CL4b chromatography, eluted in microinjection buffer containing polyamines,
and analyzed by pulse field gel electrophoresis. Pronuclear microinjection of
linear DNA was performed in fertilized C57Bl6SJL eggs which were then trans-
ferred to foster females. Offspring were genotyped by transgene-specific PCR
of DNA prepared from tail biopsies taken at the time of weaning, using oligo-
nucleotides 50-tcctggcgcccattcccaaaga-30 and 50-ccgccgcataaccagtgaaac
agc-30. Transgenic mice generated a PCR product of 1 kb. Copy number
and integrity of the transgene were analyzed by Southern blot. We obtained
10 mouse lines and retained one single copy line after characterization of
four lines that yielded similar recombination patterns after crossing with
R26R reporter (Soriano, 1999). Genotyping of the R26R was performed as
described (Soriano, 1999).
Tamoxifen Treatment
For the embryonic and neonatal fate mapping studies, time-pregnant trans-
genic females were injected with 1.5 mg 4-hydroxytamoxifen (4-OHT)
(H6278-Sigma) at the indicated embryonic stages. Noon of the vaginal plug
day was considered as E0.5. 4-OHT was prepared at 10mg/ml in 90% corn
oil and 10% ethanol. For studies in adult mice, with the exception of PDL
studies, 50 mg of tamoxifen (TM) (T5648-Sigma) was dissolved at 100 mg/ml,
with aid of sonication in 0.9% NaCl and 10% EtOH, and given orally by gavage
in three doses (20 mg, 20 mg, and 10 mg) over 1 week to 6- to 8-week-old
mice. In PDL experiments TM was delivered at 1 mg i.p. during 15 consecutive
days, or with the oral gavage protocol, yielding comparable results. We
included untreated Hnf1bCreER/R26R in all experiments and found no Lacz
leakiness or nonspecific staining for b-gal with the protocols described here.
Immunolocalization and Histochemical Procedures
Embryos or newborns were collected at indicated times, digestive tracts con-
taining the pancreas were dissected in cold PBS, then fixed 3–6 hr in 4% PFA
at 4C, washed in PBS, equilibrated in 20% sucrose at 4C, and embedded in
OCT compound. Dissected adult pancreata were washed in PBS, cut it in small
fragments, then added 4% PFA at 4C, and processed as above. For paraffin
embedding, tissues were prepared and sections were processed as described
(Boj etal., 2001;Parrizas et al., 2001). Immunofluorescenceanalysiswas done in
3 mm paraffin sections or 10mm cryosections essentially as described (Boj et al.,
2001; Parrizas et al., 2001). Immunohistochemical analysis was performed as
described in Rooman and Bouwens (2004).
The primary antibodies were: rabbit anti-Hnf1b (1:200; Santa Cruz),
mouse anti-Hnf1b (1:50; BD Transduction Labs), guinea pig anti-Insulin
(1:5000; C. Van Schravendijk), rabbit anti-glucagon (1:200; Dako), guinea pig
anti-glucagon (1:2000, Millipore), rabbit and guinea-pig anti-Ngn3 (1:1000;
M. German), rabbit anti-CPA1 (1:200; Invitrogen), goat anti-CPA1 (1:200,
R&D systems,); rabbit anti-aAmylase (1:1000; Sigma), goat anti-aAmylase
(1:200; Santa Cruz), rabbit anti-Cre (1:3000) (Kellendonk et al., 1999), chicken
anti b-galactosidase (1:500; Abcam, 9361), rabbit anti b-galactosidase (1:500;
Molecular probes), rabbit anti-Sox-9 (1:200; Santa Cruz), goat anti-Sox-9
(1:20; Santa Cruz), rat anti-cytokeratin19 (1:20,Hybridoma bank), rabbit anti-
cytokeratin (1:1000; Dako), rabbit anti-mucin1 (1:100, Santa Cruz); mouse
anti E-cadherin (1:500, Transduction Lab), mouse anti-Ki67 (1:50, BD Biosci-
ence). Secondary antibodies conjugated to Cy2, Cy3, Cy5, or TRITC were
obtained from Jackson ImmunoResearch Laboratories. The antibodies conju-
gated to Cy were used at 1:400, the antibody conjugated to TRITC was used
at 1:40. Secondary antibodies conjugated to Alexa F488 were obtained from
Invitrogen and used at 1:1000.
For 5-bromo-4-chloro-3-indolyl-D-galactoside (X-gal) staining, tissues
were processed as described above except that fixation time was reduced
to 45 min, or 4 hr for adult specimens. Cryosections were permeabilized for
30 min in 0.1 M Phosphate buffer (0.1 M NaH2PO4; 0.1 M Na2HPO4) (pH 7.3)
supplemented with 0.02% IGEPAL and incubated in 5 mM K3[Fe(CN)6];
5 mM K4[Fe(CN)6]; 2 mM MgCl2 and 0.4 mg/ml X-gal in 0.1M Phosphate
buffer (pH 7.3), for 2 hr to o/n at 37C.
Image and Statistical Analysis
Immunofluorescent stainings were analyzed with a Leica TCS 4D confocal
microscope. Images were processed with Image J software. For b-gal coloc-
alization studies, we analyzed an average of 12 nonconsecutive sections fromevier Inc.
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Plasticity of Pancreatic Duct Cellseach embryo or neonatal pancreas. For adult pancreas, we studied 8 sections
spaced to ensure a representation of all regions. b-gal-expressing cells and
pancreatic marker-expressing cells were counted separately and colocaliza-
tions were checked individually. For adult pancreas studies, we inferred the
number of acinar cells based on the area stained by amylase. To correct for
minor variations in labeling efficiency between samples, b-gal labeling rates
for different cell types were normalized to the labeling rate of Hnf1b+ cells.
For X-gal-stained sections we determined the total number of CK19 or
insulin-expressing cells by immunofluorescence, and then quantified the
subset that were X-gal positive by light microscopy. b cell mass was calculated
as described (Rooman and Bouwens, 2004).
Statistical significance of cell-specific changes in b-gal expression in label
and chase periods or X-gal in control versus ligated pancreas was calculated
by an unpaired Student’s t test. All results are expressed as mean ± SEM.
Regeneration Procedures
We performed pancreatic duct ligations (PDL) in seven 7-week-old male mice
and seven sham operated mice exactly as in (Xu et al., 2008; Wang et al.,
1995), 3 weeks after TM treatment as described above. One week after ligation
animals were killed and processed for immunolocalization and X-gal analysis.
We also treated eleven 7-week-old male mice with TM, and 2 weeks later
injected alloxan (70 mg/kg i.v.). One day later EGF + gastrin treatment (n = 5)
with i.p. implanted Alzet miniosmotic pumps or pumps with solvent only
(n = 6) (control mice) was initiated as described (Rooman and Bouwens,
2004). These pumps release their content for approximately 1 week, at which
time mice were analyzed, coinciding when b cell mass has reached a peak
(Rooman and Bouwens, 2004).
RNA Analysis
Total RNA was extracted from tissues with TRIzol (Invitrogen). RNA quality was
controlled with a 2100 Bioanalyzer (Agilent). cDNA synthesis was performed
with reagents from the Verso Sybr 2-Step QRT rox kit (Thermo Fisher Scien-
tific) after DNA removal with DNA-free (Ambion). Real-time PCR reactions
were then performed with cDNA corresponding to 20 ng RNA as described
in (Xu et al., 2008). Data were normalized to cyclophilin A, and duodenum
cDNA was used as a positive control reference for Ngn3 expression.
SUPPLEMENTAL DATA
Supplemental Data include four figures and one table and can be found with
this article online at http://www.cell.com/developmental-cell/supplemental/
S1534-5807(09)00477-8.
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